Robo Global Healthcare Technology and… (HTEC) Valuation
HTEC valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 93.9 trailing earnings
- Forward P/E
- 21.6 analyst estimates
- Price / sales
- 4.44
- Price / book
- 4.01
- EV / EBITDA
- 17.3
- Earnings yield
- 1.07% inverse of P/E
- Dividend yield
- 0.25% of the holdings
- Return on equity
- 4.3% combined
- Net margin
- 4.7% combined
- Beta
- 1.19 weighted, vs S&P 500
HTEC valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| HTEC | 93.9 | 21.6 | 4.44 | 4.01 | 0.25% | 4.3% | 4.7% | 34.6% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
HTEC valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 97.0% | 94.1 | 22.3 | 4.44 | 4.03 | 0.26% | 4.3% |
| Technology | 1.4% | 81.5 | 8.4 | 4.73 | 3.38 | 0.00% | 4.1% |
HTEC earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How HTEC weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
HTEC largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| GRAL | GRAIL, Inc. | 2.61% | — | — | 31.8 | — | −25.19% |
| NTRA | Natera, Inc. | 2.46% | — | — | 20.9 | — | −0.99% |
| MRNA | Moderna, Inc. | 2.40% | — | 23.0 | 39.1 | — | −10.29% |
| ISRG | Intuitive Surgical, Inc. | 2.31% | 48.9 | 33.3 | 13.7 | — | 5.53% |
| TWST | Twist Bioscience Corporation | 2.25% | — | — | 20.4 | — | −4.44% |
| ILMN | Illumina, Inc. | 2.08% | 49.0 | 40.3 | 8.8 | — | 4.98% |
| TMO | Thermo Fisher Scientific Inc. | 2.05% | 37.1 | 24.2 | 5.5 | 0.27% | 6.47% |
| MEDP | Medpace Holdings, Inc. | 1.95% | 36.3 | 31.9 | 6.2 | — | 6.30% |
| LONN | Lonza Group AG | 1.95% | — | — | — | — | — |
| SHL | Siemens Healthineers AG | 1.95% | — | — | — | — | — |
| SYK | Stryker Corporation | 1.93% | 30.5 | 16.5 | 4.4 | 1.19% | 7.41% |
| CDNA | CareDx, Inc | 1.91% | 30.8 | 156.2 | 7.2 | — | 7.29% |
| GH | Guardant Health, Inc. | 1.86% | — | — | 18.0 | — | −4.80% |
| TEM | Tempus AI, Inc. | 1.83% | — | — | 8.2 | — | −4.65% |
| LIVN | LivaNova PLC | 1.83% | 23.0 | 16.0 | 2.9 | — | 9.33% |
| PHIA | Koninklijke Philips NV | 1.83% | — | — | — | — | — |
| TECN | Tecan Group AG | 1.80% | — | — | — | — | — |
| DHR | Danaher Corporation | 1.77% | 40.8 | 23.8 | 6.4 | 0.70% | 5.07% |
| BSX | Boston Scientific Corporation | 1.76% | 18.0 | 13.2 | 3.1 | — | 11.49% |
| IQV | IQVIA Holdings Inc. | 1.75% | 33.2 | 18.4 | 2.6 | — | 6.18% |
| ADPT | Adaptive Biotechnologies Corporation | 1.74% | — | — | 12.4 | — | −3.47% |
| GMED | Globus Medical, Inc. | 1.73% | 19.7 | 13.9 | 3.3 | — | 10.33% |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.73% | 19.6 | 14.5 | 5.2 | 0.48% | 10.38% |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.73% | 28.9 | 24.1 | 10.1 | — | 7.01% |
| A | Agilent Technologies, Inc. | 1.72% | 34.1 | 23.9 | 6.6 | 0.59% | 5.91% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About HTEC valuation
Adding up its 48 holdings with company data, HTEC trades at 93.9 times trailing earnings and 21.6 times analysts' forward estimates, with a price-to-book ratio of 4.01 and a dividend yield of 0.25%. Its earnings yield of 1.07% is 4.26 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 22.0% of the fund and earn −2.9% of its combined profit. By sector, Healthcare is the most expensive at 94.1 times earnings and Technology the cheapest at 81.5. Companies that lost money over the past year are 34.6% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 81.1% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: HTEC chart, HTEC performance, HTEC holdings, HTEC dividends.
HTEC valuation FAQ
What is the P/E ratio of HTEC?
Based on its holdings, HTEC has a trailing P/E of 93.9 and a forward P/E of 21.6 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of HTEC?
The trailing earnings yield is 1.07% (1 ÷ P/E) and the forward earnings yield 4.64%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is HTEC more expensive than the S&P 500?
HTEC trades at 93.9 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 21.6 and 19.9.
What is the price-to-book ratio of HTEC?
The holdings of HTEC trade at 4.01 times book value, with a combined return on equity of 4.3%.
Which sector in HTEC has the highest P/E?
Healthcare has the highest P/E at 94.1 and Technology the lowest at 81.5.